Hitting the Mark - Individualizing Therapy for HER2-Positive Early-Stage Breast Cancer

N Engl J Med. 2026 Feb 26;394(9):918-920. doi: 10.1056/NEJMe2600247.
No abstract available

Publication types

  • Editorial